FilingReader Intelligence
Changchun High & New Tech unit gets nasal flu vaccine approval
August 25, 2025 at 08:11 PM UTC•By FilingReader AI
Changchun High & New Technology Industry Group announced its subsidiary Changchun Boke Biological Technology has received marketing authorization for its nasal spray attenuated live influenza vaccine.
The liquid formulation is for intranasal use in individuals aged 3 to 17 years, eliminating the need for reconstitution during administration.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000661•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Changchun High & New Technology Industry Group publishes news
Free account required • Unsubscribe anytime